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CDK9, the kinase of positive transcription elongation
factor b (P-TEFb), stimulates transcription elongation
by phosphorylating RNA polymerase II and tran-
scription elongation factors. Using kinetic analysis
of a human P-TEFb complex consisting of CDK9
and cyclin T, we show that the CDK9 C-terminal tail
sequence is important for the catalytic mechanism
and imposes an ordered binding of substrates and
release of products. Crystallographic analysis of
a CDK9/cyclin T complex in which the C-terminal
tail partially blocks the ATP binding site reveals
a possible reaction intermediate. Biochemical char-
acterization of CDK9 mutants supports a model in
which the CDK9 tail cycles through different confor-
mational states. We propose that this mechanism is
critical for the pattern of CTD Ser2 phosphorylation
on actively transcribed genes.
INTRODUCTION
Transcription of protein coding genes by RNA polymerase II
(Pol II) is a highly regulated process. Transcription is regulated
by the recruitment of Pol II not only during transcription initiation
but also during elongation. On many genes, Pol II pauses during
early transcription elongation. Genome-wide studies in murine,
human, and Drosophila cells have revealed that such promoter
proximal pausing is a widespread mechanism that regulates
the rate of gene transcription (Core et al., 2008; Nechaev and
Adelman, 2011; Price, 2008).
Promoter proximal pausing is reversed by the activity of
P-TEFb, a complex of cyclin-dependent kinase 9 (CDK9) and
cyclin T1 or T2. The enzyme phosphorylates the elongation
factors DSIF (5,6-dichlorobenzimidazole 1-b-D-ribofuranoside
[DRB]-sensitivity-inducing factor), and NELF (negative elonga-
tion factor) (Peterlin and Price, 2006; Zhou and Yik, 2006) as
well as Ser2 within the heptad repeat sequence in the C-terminal
domain (CTD) of the largest Pol II subunit. These phosphorylation
events release paused Pol II and allow productive transcription
elongation. The CTD is a binding platform for the recruitment
of transcription, RNA processing, and histone-modifying factors.
CDK7–CDK9, CDK12, and CDK13 phosphorylate specific resi-
dues within the CTD heptad repeats. Changes in the phosphor-
ylation pattern are linked to progression through the different
stages of transcription and serve to recruit the appropriate1788 Structure 20, 1788–1795, October 10, 2012 ª2012 Elsevier Ltdtranscription factors (Buratowski, 2009; Meinhart et al., 2005).
Although it is clear that different CTD residues are phosphory-
lated at distinct stages in the transcription cycle, it remains to
be determined how many of the 52 repeats are phosphorylated
and whether patterns of phosphorylation occur.
The structures of the conserved core domains of cyclins T1
and T2 and of a CDK9/cyclin T1 complex provide insights into
P-TEFb organization (Anand et al., 2007; Baumli et al., 2008).
CDK9 adopts a typical protein kinase fold, whereas cyclin T has
a canonical cyclin structure. The CDK9-cyclin T1 interface is
restricted to the N-terminal kinase lobe and is notably smaller
than in other CDK/cyclin complexes, leading to greater confor-
mational flexibility of the kinase structure. Complexes between
CDK9/cyclin T and HIV-1 TAT or ATP-competitive inhibitors
reveal that CDK9 can undergo structural changes in response
to regulator binding (Baumli et al., 2008, 2010; Bettayeb et al.,
2010; Tahirov et al., 2010). Such conformational plasticity has
been documented for a number of protein kinases and is a char-
acteristic of the protein kinase fold that is often exploited by regu-
latory factors (Endicott et al., 2012; Huse and Kuriyan, 2002).
In addition to the protein kinase fold, CDK9 has a C-terminal
tail (residues 331–372; Figure 1A) with a largely nonconserved
sequence. This tail is required for the nuclear import of P-TEFb
(Napolitano et al., 2003) and for high-affinity binding to HIV
TAT/TAR (Garber et al., 2000). CDK9/cyclin T nuclear import
and association of CDK9/cyclin T/TAT with TAR RNA are depen-
dent on autophosphorylation of several sites within the tail
(Garber et al., 2000). However, the phosphorylation status of
these sites does not affect CDK9 activity toward the Pol II CTD
measured in vitro (Baumli et al., 2008).
To understand howCDK9 phosphorylates themultiple repeats
in the Pol II CTD, we focus here on the kinetic mechanism.
We show that the CDK9 C-terminal tail defines the catalytic
mechanism. It ensures that CDK9-catalyzed phosphotransfer
proceeds through sequentially ordered formation of a ternary
enzyme/ATP/CTD complex. We present the structure of P-
TEFb, including the CDK9 C-terminal tail, which was truncated
in previous structures. We find that binding of the ATP-compet-
itive inhibitor DRB selectively stabilizes a CDK9 conformation in
which the C-terminal tail is structured and folds over the ATP
binding site. Analysis of CDK9 C-terminal tail mutants show
that this bound conformation is a prerequisite for the observed
ordered kinetic mechanism and represents a possible reaction
intermediate. A consequence of this mechanism is that the
phosphorylated CTD is released from the CDK9 active site after
each catalytic turnover. We propose that this mechanism affects
the distribution of Ser-2 phosphorylated sites on the Pol II CTD
and thereby specifies recruitment of CTD-binding proteins.All rights reserved
Figure 1. The C Terminus of CDK9 Influ-
ences Kinase Activity
(A) Sequence alignment of the C-terminal region
of CDK9. Identical residues are highlighted in
green, and chemically equivalent residues are in
yellow. The location of the most C-terminal CDK9
a helix is shown above the alignment. The con-
structs used in (B) and (C) are identified below the
alignment.
(B) Activity of CDK9FL/cyclin T and CDK9330/cyclin
T assayed in the presence of increasing amounts
of ATP.
(C) Activity of various CDK9/cyclin T complexes
with increasing concentrations of GST-CTD.
CDK9 variants are labeled as shown in (A). All
measurements were done in triplicate and repro-
duced in independent experiments. Error bars
indicate standard errors (SEs). For a summary of
the apparent kinetic parameters, see Table S1.
See also Figure S1.
Table 1. Overall Kinetic Parameters
CDK9FL/cyclin T
KM, ATP 329 ± 55 mM
KM, CTD 115 ± 17 mM
KATP 21 ± 9 mM
Kcat/KM,ATP 0.55 min
1mM1
Kcat/KM,CTD 1.6 min
1mM1
Kcat 178 ± 19 min
1
KATP, KM, CTD, and KM, ATP correspond to the ATP dissociation constant
and Michaelis constants for GST-CTD and ATP, respectively. The corre-
sponding raw data are shown in Figure S2. Akaike’s information criterion
as implemented in Graphpad Prism (www.graphpad.com) was used to
distinguish between ternary complex and substituted enzyme mecha-
nisms. The data are compatible with the ternary complex mechanism
(probability: 96%).
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The CDK9 C-Terminal Tail Is Important for CDK9 Kinase
Activity
To analyze the function of the CDK9 C-terminal sequence, we
expressed and purified full-length human CDK9 (residues 1–
372, CDK9FL) and compared its activity with that of the trun-
cated CDK9 construct CDK9330 (residues 1–330) for which
structural information is available. Both forms of CDK9 were
bound to truncated cyclin T (residues 1–288, cyclin T) and kinase
activity was measured against a GST-tagged version of the
human Pol II CTD (GST-CTD). At an ATP concentration of
100 mM, CDK9330 has only 30% of the kinase activity of the
full-length protein (Figure S1A available online). Further enzy-
matic analysis revealed that this difference in activity does not
result from differences in affinity toward GST-CTD, because
both CDK9330 and CDK9FL have very similar KM,app (apparent
KM value at a fixed concentration of the second substrate)
values for this substrate (21.3 ± 3.7 mM versus 24.3 ± 2.7 mM,
respectively; Figure S1B). In contrast, CDK9FL shows a much
lower KM,app toward ATP than truncated CDK9330 (KM,app ATP
CDK9FL 160 ± 13 mM; KM,app ATP CDK9330 > 1 mM; Figure 1B;
Table S1). The tail-length dependence of only the maximal
velocity (Vmax), and not KM, with respect to the Pol II CTD
indicates that the C-terminal sequence is not involved in recog-
nition of the peptide substrate. Furthermore, the dependence of
KM as well as Vmax with respect to the ATP substrate indicates
that the C-terminal tail influences ATP binding and catalysis
(Cornish-Bowden, 2004).
To analyze which region of the C-terminal tail is important
for the observed change in kinase activity, we constructed
a series of CDK9 truncations (Figure 1A). Analysis of these
constructs at an ATP concentration of 100 mM revealed a
gradual loss of activity toward GST-CTD as the C-terminal tail
is shortened (Figure 1C; Table S1). Consistent with the mecha-
nism described above, all truncations show similar KM,app
values, but a gradual decrease in Vmax,app toward the GST-Structure 20, 1788–1CTD substrate. These results demonstrate that the length
of the C-terminal tail affects the apparent kinetic parameters
of CDK9.
Deletion of the CDK9 Tail Changes the Kinetic
Mechanism
To better understand the molecular mechanism of phosphory-
lation by CDK9, we analyzed kinase activity by varying the con-
centrations of both GST-CTD and ATP substrates. An analysis
of the initial rate experiments demonstrates that, in agreement
with what is generally observed for protein kinases (Adams,
2001), the reaction curves are consistent with a ternary complex
mechanism, in which a complex containing both substrates
bound to the kinase is formed during catalysis (Table 1;
Figure S2).
To investigate whether the order of substrate binding and
release is important for the catalytic mechanism, we carried
out product inhibition experiments using low concentrations
of ADP. If both substrates bind to the kinase in a random795, October 10, 2012 ª2012 Elsevier Ltd All rights reserved 1789
Figure 2. The CDK9 Tail Is Required for
the Ordered Substrate Addition Catalytic
Mechanism
(A) Theoretical model curves for mixed and
competitive inhibition assuming the same KM, Ki,
and Vmax in both cases.
(B) Activity of CDK9FL/cyclin T in the absence and
presence of 2.5 mM ADP, in the presence of
100 mM ATP and increasing amounts of CTD.
(C) Activity of CDK9FL/cyclin T in the absence and
presence of 2.5 mMADP, in the presence of 36 mM
CTD and increasing amounts of ATP.
(D) Activity of CDK9330/cyclin T in the absence
and presence of 2.5 mM ADP, in the presence
of 100 mM ATP and increasing amounts of CTD.
All measurements were done in triplicate and
reproduced in independent experiments.
Error bars in (B)–(D) represent SEs. See also
Figure S3.
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Kinetic and Mechanistic Characterization of CDK9order, then the ADP product should act as a competitive
inhibitor with respect to both the ATP and the GST-CTD
substrates. If substrate binding to the enzyme is ordered,
then ADP should not compete with both substrates, and the
inhibition mechanism toward either one should be dependent
on the sequence of substrate addition (Cornish-Bowden,
2004).
These experiments revealed that ADP is a potent CDK9
inhibitor with a low micromolar Ki (Figure 2B). ADP inhibits
CDK9FL with respect to the GST-CTD substrate by decreasing
Vmax and increasing KM, which is characteristic of a mixed
inhibition mechanism (Figures 2A and 2B). However, ADP acts
as a competitive CDK9 inhibitor with respect to the substrate
ATP (Figures 2A and 2C). These results are consistent with
a reaction that proceeds through an ordered recruitment of
substrates, with ATP being the first substrate to be bound
and ADP the second product to be released. Of interest,
a different behavior is observed for the CDK9 C-terminal dele-
tion: ADP inhibits competitively with respect to both substrates
(Figure 2D), indicating that they bind to CDK9330 in a random
order. Taken together, these results suggest that the CDK9
C-terminal tail ensures that the reaction follows a compulsory
order ternary complex mechanism during which ATP binds
first to the kinase followed by the CTD and that following
catalysis, the phosphorylated CTD is the first product to be
released.1790 Structure 20, 1788–1795, October 10, 2012 ª2012 Elsevier Ltd All rights reservedThe CDK9 C-Terminal Tail
Becomes Structured upon Binding
to an Active Kinase Conformation
To date, P-TEFb structures have been
determined using truncated CDK9 and
cyclin T that were engineered to improve
crystal quality. In these structures, elec-
tron density for the C-terminal sequence
of CDK9 is either missing after residue
325 (Baumli et al., 2008) or extends
away from the CDK9 fold and adopts
a structure that is determined by crystal
contacts (Tahirov et al., 2010; Figure S4).In order to understand the molecular mechanism by which the
C-terminal tail controls CDK9 activity, we solved the structure
of apo CDK9FL/cyclin T259 (residues 1–259) at a resolution of
3.2 A˚ (Table 2; Figure 3A). As expected, the cores of both
subunits of the complex closely resemble the previously pub-
lished CDK9330/cyclin T259 structure (Baumli et al., 2008). Addi-
tional electron density is observed for CDK9 residues 326–327,
which form an a-helical turn at the back of CDK9. The electron
density gradually weakens after residue 327, and further resi-
dues could not be built with confidence. This result indicates
that the CDK9 C-terminal tail is inherently flexible.
We recently showed that the CDK9-specific inhibitor DRB
is a more potent inhibitor of CDK9FL than of CDK9330, and
stabilizes CDK9FL (Baumli et al., 2010). By soaking DRB into
preformed CDK9FL/cyclin T259 crystals, we aimed to exploit
this stabilizing effect to observe the CDK9 C-terminal tail resi-
dues. The resulting crystal structure, solved at 3.6 A˚ resolution,
shows unambiguous electron density for the inhibitor and 11
additional CDK9 C-terminal residues as compared with the
structure of CDK9FL/cyclin T259 (Table 2; Figures 3B–3D). Super-
position of the two DRB-bound structures shows that the DRB
binding mode is unaffected by the C-terminal tail, and that
apart from some CDK9 flexibility at the tip of the glycine-rich
loop, the structures close to the ATP-binding site (as seen in
PDB: 3BLH) are very similar (root mean-square deviation
[rmsd] = 0.946 over all CDK9 atoms when compared with
Table 2. Data Collection and Refinement Statistics
CDK9FL/cyclin T/DRB CDK9FL/cyclin T
Data Collection
Space group H3 H3
Cell dimensions
a, b, c (A˚) 175.1, 175.1, 101.3 174.3, 174.3, 97.9
a, b, g () 90, 90, 120 90, 90, 120
Resolution (A˚) 60.69–3.6 (3.79–3.6) 46.6–3.2 (3.38–3.2)
Rmerge 0.12 (0.77) 0.051 (0.514)
I / sI 4.7 (1.4) 11.7 (1.5)
Completeness (%) 98.2 (99.3) 98.9 (98.2)
Redundancy 2.1 (2.1) 2.8 (2.9)
Refinement
Resolution (A˚) 49.87–3.6 46.60–3.21
Number of reflections 13,155 17,257
Rwork / Rfree 19.2 / 23.0 20.1 / 23.32
Number of protein atoms 4,700 4,534
B-factors (A˚2) 125.7 144
rmsd
Bond lengths (A˚) 0.008 0.008
Bond angles () 1.073 1.456
Values in parentheses are for highest-resolution shell.
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Kinetic and Mechanistic Characterization of CDK9PDB: 3MY1) (Baumli et al., 2010; Figure 3E). CDK9 adopts
a closed state upon DRB binding in which the N-terminal lobe
is rotated by 8 with respect to the apo or ATP-bound structure.
This closed state is stabilized in the context of CDK9FL by
folding of the C-terminal tail over the ATP binding site (Figures
3B and 3D). The CDK9 C-terminal sequence makes no direct
contacts with DRB. However, the DRB-bound CDK9 conforma-
tion is stabilized by Phe336 and Glu337, two strictly conserved
residues that form a clamp around the CDK9 hinge region, close
to where ATP is observed in PDB: 3BLH (Figure 3E). Phe336
inserts into a hydrophobic pocket just before the hinge, and
Glu337 inserts into the ATP binding site. Correct alignment of
the N- and C-terminal lobes is an important mechanism of
regulation for many kinases (Huse and Kuriyan, 2002). The orien-
tation of the CDK9 N- and C-terminal lobes induced by DRB
binding is characteristic of protein kinase and protein kinase/
substrate complexes that are poised for catalysis. This structure
may be further stabilized by the binding of the C-terminal tail.
These observations are consistent with a role for the CDK9
C-terminal tail in the catalytic mechanism.
Conformational Cycling of the CDK9 C-Terminal Tail Is
Required for the CDK9 Catalytic Cycle
To test whether the bound conformation of the C-terminal tail
that we observed in our structural studies is relevant for the
kinase mechanism, we mutated the clamp-forming residues
Phe336 and Glu337. In one mutant, each residue was sub-
stituted by alanine (CDK9AA), and in another mutant, Phe336
and Glu337 were changed to an aspartate and alanine, respec-
tively (CDK9DA). Mutation to an aspartate introduces a charged
residue that can no longer be accommodated in the hydrophobic
pocket. At low ATP concentrations, both mutants exhibited onlyStructure 20, 1788–130% of the kinase activity of the full-length protein toward
GST-CTD, demonstrating that these two conserved residues
are required for optimal CDK9 activity. The low activity observed
for the clamp mutants under these conditions is similar to that of
CDK9330 (Figure 4A). As observed with CDK9330, ADP acts as
a competitive inhibitor of CDK9DA with respect to the CTD
substrate (Figure S3). This result indicates that mutation of the
clamp residues changes the CDK9 kinetic pathway despite the
presence of the C-terminal tail. Taken together, our results
suggest that the bound state of the C-terminal tail and the
associated kinase conformation observed in the CDK9FL/cyclin
T259/DRB complex represents a conformation that is adopted
during the reaction cycle.
To confirm that the position of the C-terminal tail in its bound
conformation does not interfere with binding of either substrate
and thus is compatible with substrate turnover, we modeled
ATP and a substrate peptide into this structure. Figures 3E and
4B show that the conformation of the C-terminal tail is compat-
ible with binding of both ATP and the substrate peptide, which
binds against the activation segment at the other end of the
ATP binding pocket (Baumli et al., 2008).
The only close contact occurs between ATP and the glycine-
rich loop (CDK9 residues 26–33), a mobile region that has been
shown to adopt a number of different conformations (Baumli
et al., 2008, 2010; Tahirov et al., 2010). In this model, the ATP
binding site is fully enclosed by the substrate peptide from one
side and the C-terminal tail from the other side. The model also
suggests that the C-terminal sequence has to unlock from this
position to allow the exchange of ADP and ATP. This analysis
suggests that a degree of conformational flexibility of the
C-terminal tail, as observed in the apo and the ATP-bound
crystal structures, is required for CDK9 activity.
DISCUSSION
We have shown that conformational cycling of the C-terminal
tail is essential for CDK9 to proceed through an ordered kinetic
pathway (Figure 5). We propose that the DRB-bound structure
of CDK9/cyclin T reported here represents a short-lived confor-
mational state that is adopted during the phosphorylation
cycle. The C terminus transiently folds over the ATP binding
site, thereby stabilizing the N- and C-terminal kinase lobes
and promoting ATP binding. The relevance of this structure
for the catalytic mechanism was corroborated by mutation
of contacting residues in the CDK9 tail. Conformational transi-
tions are essential elements of the reaction mechanisms of
protein kinases, and the closing together of the N- and
C-terminal lobes is a characteristic structural feature of protein
kinase activation (Huse and Kuriyan, 2002). Like CDK9, protein
kinase A (PKA), the prototypic protein kinase, undergoes a rear-
rangement of its C-terminal tail to stabilize a closed kinase
conformation (Hyeon et al., 2009). Although the C-terminal
sequences of CDK9 and PKA are unrelated in sequence and
structure, both play a role in stabilizing the kinase conformation
during the catalytic cycle.
Studies of the kinetic mechanisms of a number of protein
kinases have consistently shown that these kinases go through
a ternary complex rather than employing a ‘‘ping-pong’’ mecha-
nism to effect phosphotransfer. Upon further examination,795, October 10, 2012 ª2012 Elsevier Ltd All rights reserved 1791
Figure 3. Structure of the CDK9 C-Terminal
Tail
(A) The final electron density map corresponding
to additional C-terminal residues present in
CDK9FL bound to cyclin T259 in the absence of
DRB or AMPPNP is shown as a blue mesh at
a contour level of 1s. The difference density is
shown as a green mesh at a contour level of 3s.
The CDK9 core structure is displayed as a solvent-
accessible surface representation in gray.
(B) Same view as in (A) to show the electron
density corresponding to the CDK9 C-terminal
sequence present in the structure of CDK9FL/cy-
clin T259 bound to DRB. The electron density map
is drawn as a blue mesh and contoured at 1s.
(C) Detailed view of the interactions between the
CDK9 C-terminal residues and the hinge
sequence present in the CDK9FL/cyclin T259/DRB
complex. The solvent-accessible surface of
CDK9330 is drawn in gray and selected residues
are labeled. The electron density map of the
refined structure is drawn at a contour level of 1s.
(D) The difference density map corresponding to
the DRB binding site in CDK9FL is shown at a
contour level of 3s. Residues of the CDK9FL hinge
region (from Phe103 to Glu107) are also shown.
(E) Interactions of Phe336 and Glu337 with the
CDK9 hinge region. C-terminal residues that are
identical across species are drawn as sticks in
green, andequivalent residuesare in yellow.CDK9/
cyclin T259 (PDB 3BLH) bound to ATP is super-
posed in blue for comparison. See also Figure S4.
Figure 4. Flexibility of the CDK9 C Terminus Is Important for Kinase
Activity
(A) Activity of CDK9FL/cyclin T toward GST-CTD compared with complexes
containing the CDK9 clamp mutants CDK9AA and CDK9DA, and the CDK9
truncation CDK9330. All measurements were done at 100 mM ATP and 24 mM
GST-CTD in triplicate and reproduced in independent experiments. Error bars
represent SEs.
(B) Model showing that binding of a substrate peptide (lilac) is compatible with
the bound conformation of the CDK9 C-terminal region. In this model, Ser2 of
the heptad repeat occupies the phosphotransfer position. The cartoon-and-
stick model is as described in Figure 3E.
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Kinetic and Mechanistic Characterization of CDK9however, the kinetic mechanisms appear to differ as to whether
substrate binding and product release follow an ordered or
random pathway (Clare et al., 2001; Konstantinidis et al.,
1998). PKA has beenmost extensively studied in order to identify
the protein kinase-catalyzed rate-limiting step. This enzyme has
been shown to follow a reaction pathway in which the chemical
step is fast and the rate-limiting step is the release of ADP (Zhou
and Adams, 1997). Our results are compatible with the notion
that this step is also rate limiting for P-TEFb turnover.
Of note, although they are closely related in sequence and
structure, members of the CDK family do not follow the same
kinetic pathway. Studies on CDK2 and CDK5 have demon-
strated that ATP and peptide substrate binding is random (Clare
et al., 2001), whereas CDK4 proceeds through an ordered
sequential mechanism in which ATP is the first substrate to
be bound and the phosphoprotein is the last product to be
released (Konstantinidis et al., 1998). Our results suggest that
CDK9 catalysis also proceeds through an ordered mechanism
but differs from CDK4 in that after the catalytic step, the
phosphorylated protein is the first product to leave the enzyme
active site.
The Pol II CTD presents CDK9 with multiple phosphorylation
sites on a single polypeptide. A mechanism that releases the
protein product prior to releasing ADP disfavors scanning of
the protein substrate and may therefore affect the distribution
of phosphorylated Ser2 sites throughout the CTD, especially if
the rate of ADP dissociation is slow. Thus, an ordered mecha-
nism would be predicted to lead to phosphorylation of discrete
sites distributed along the CTD, rather than to sequential phos-
phorylation of consecutive sites.1792 Structure 20, 1788–1795, October 10, 2012 ª2012 Elsevier LtdIt was recently reported that p-TEFb can phosphorylate Ser5
on the CTD substrate in vitro and is unable to phosphorylate
a CTD that has been prephosphorylated at Ser5 or Ser2 (Czud-
nochowski et al., 2012). Our models of peptide-bound CDK9
support the notion of a Ser2/Ser5 dual specificity and can to
some extent rationalize the observation that there are no Ser2
and Ser5 phosphorylations in the same repeat (see ResultsAll rights reserved
Figure 5. Model of the CDK9 Catalytic Cycle
(A) Model of the CDK9 conformational states adopted during the catalytic
cycle. The cyclin subunit is omitted from the scheme for clarity. (I) Apo CDK9
has a flexible C-terminal tail. ATP is the first substrate bound to CDK9. (II) Upon
ATP binding, the CDK9 C-terminal tail adopts an ordered structure, partially
covering the ATP binding site. (III) The Pol II CTD binds to the CDK9/ATP
complex to form a ternary complex that is competent for phosphotransfer. (IV)
After phosphorylation, the CTD substrate is released. (V) ADP is released and
the kinase returns to its apo state with a flexible C-terminal tail.
(B) Reaction scheme. k1 and k-1 refer to the rate constants for ternary complex
formation, and k2 is the rate constant governed by phosphotransfer and
product release.
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Kinetic and Mechanistic Characterization of CDK9section of the Supplemental Information). The CDK9 Ser2
specificity observed in vivo may be due to additional factors or
the C-terminal sequence in cyclin T that are absent in the
in vitro system. Further results reported by Czudnochowski
et al. (2012) support a mechanism of CTD phosphorylation by
P-TEFb that is distributive. The results presented here are
consistent with such a model.
The CTD serves as a binding platform for transcription and
RNA processing factors, and the phosphorylation pattern of
the multiple repeats determines which factors bind. Recently,
it was shown that in yeast, the transcription termination factors
Rtt103 and Pcf11 achieve high affinity and specificity both by
specifically recognizing the Ser2 phosphorylated CTD and by
cooperatively binding to neighboring CTD repeats. This coop-
erativity is thought to ensure that binding is confined only to
authentic polyadenylation sites where Ser2 phosphorylation
density is highest (Lunde et al., 2010). CDK9 begins to phos-
phorylate the CTD close to the 50 end of the gene, and at this
stage it may be advantageous for the cell to phosphorylate
only discrete repeats rather than most or all repeats. Recently,
CDK12 and CDK13 were identified as CTD Ser2 kinases and
metazoan orthologs of yeast Ctk1 (Bartkowiak et al., 2010;
Blazek et al., 2011). In contrast to CDK9, which locates to the
50 end of the gene, CDK12 occupancy increases toward the
30 end and may account for the high Ser2 phosphorylation in
this region.
Sequence alignment shows that CDK7–CDK9, CDK12, and
CDK13 all have an extended C-terminal tail beyond the canon-
ical protein kinase fold. A prediction of our model is that although
these regions are not conserved in sequence, they could impose
a shared kineticmechanism that would also directly contribute to
the pattern of CTD phosphorylation. Upon loss of the C-terminalStructure 20, 1788–1tail, the CDK9 sequence is now similar to CDK2 and CDK5, both
of which encode little more than the core protein kinase catalytic
fold. Like these shorter CDKs, CDK9330 follows a random
substrate-binding model.
In vivo, the CDK9 C-terminal tail is (auto)phosphorylated at
several positions (http://www.phosida.com; Gnad et al., 2011).
Although our experiments using prephosphorylated CDK9
have shown that the phosphorylation status of the CDK9 tail
does not affect P-TEFb activity in vitro (Baumli et al., 2008),
phosphorylation of the CDK9 C-terminal tail is required for the
binding of HIV TAR RNA to P-TEFb (Garber et al., 2000). It
remains to be determined whether this phosphorylation also
affects the recruitment of endogenous regulatory proteins. A
further prediction from our results is that the binding of such
proteins to the CDK9 C-terminal tail could change the kinetic
mechanism of P-TEFb. This change could in turn alter the phos-
phorylation patterns on the Pol II CTD and the complement of
transcription factors bound to it.EXPERIMENTAL PROCEDURES
Protein Variants, Expression, and Purification
C-terminally truncated (residues 1–330, CDK91-330) and full-length CDK9
(CDK9FL) in complex with cyclin T (residues 1–259, cyclin T259; residues 1–
288, cyclin T) were expressed and purified as previously described (Baumli
et al., 2008). Cyclin T constructs that are optimal for crystallization and contain
the mutations Q77R/E96G/F241L were used throughout. We previously
characterized this variant crystallographically and enzymatically (Baumli
et al., 2012). The validity of the kinetic mechanism described in this work
was confirmed using cyclin T encoding for the wild-type sequence. Recombi-
nant baculoviruses for generation of the C-terminally truncated CDK9 proteins
were generated using the BD Baculo gold system (BD Biosystems). The CDK9
mutants were prepared using the QuikChange XL kit (Stratagene) according
to the manufacturer’s instructions. All constructs were verified by DNA
sequencing. A GST-tagged construct of the Pol II CTD encoding residues
C-terminal of residue 1586 (GST-CTD; further details are provided in the
Supplemental Experimental Procedures section of the Supplemental Informa-
tion) was expressed in BL21 DE3 cells overnight in TB medium at 18C after
induction with 0.2 mM isopropylthio-b-D-thiogalactoside (IPTG). The cell
pellets were resuspended in CTD buffer (20 mM Tris pH 8.0, 300 mM NaCl,
5 mM dithiothreitol [DTT], and complete protein inhibitor cocktail [Roche]),
lysed by sonication, and purified by glutathione affinity chromatography.Crystallization and Structure Determination
CDK9FL/cyclin T259 was concentrated to 4 mg/ml in a buffer containing 20 mM
Tris pH 8.0, 500 mM NaCl, 10% glycerol, and 5 mM DTT, and crystallized
at 4C in sitting drops. CDK9FL/cyclin T259 was crystallized in 1% PEG 1K,
180–200 mM sodium/potassium phosphate pH 6.2, 4 mM tris(2-carbox-
yethyl)phosphine) (TCEP). To prepare the DRB complex, preformed crystals
were soaked overnight in 3.6% PEG 1K, 162 mM sodium/potassium phos-
phate pH 6.2, 4 mM TCEP, 23.4% glycerol, and 200 mM DRB (resuspended
in water), and then cryocooled in liquid nitrogen. Data were collected for the
CDK9FL/cyclin T259/DRB and CDK9FL/cyclin T259 complexes at beamlines
ID29 and ID14-4 of the European Synchrotron Radiation Facility. Data were
processed and integrated using MOSFLM and SCALA to 3.6 and 3.2 A˚ reso-
lution, respectively. For the CDK9FL/cyclin T259/DRB crystal structure, strong
electron density corresponding to the inhibitor was seen at the CDK9 ATP
binding site after initial rigid-body and TLS refinement using PHENIX.refine
(Adams et al., 2010) and using the CDK9330/cyclin T259 apo structure (PDB:
3BLH) as the initial model. Final models were generated by alternative cycles
of rebuilding in COOT (Emsley and Cowtan, 2004) and refinement using
PHENIX.refine. Invariant regions in the CDK9FL/cyclin T259/DRB structure
were refined by rigid-body and TLS refinement. The glycine-rich loop, the
aC-b3 loop, and the C terminus (residues 325–340) of CDK9, as well as cyclin795, October 10, 2012 ª2012 Elsevier Ltd All rights reserved 1793
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Kinetic and Mechanistic Characterization of CDK9T259 residues 150–157, were built in COOT, and coordinate and B-factor
refinement was performed on those regions only.
Kinase Assays
CDK9/cyclin T activity was measured by incorporating radiolabeled phos-
phate into substrate GST-CTD containing 52 heptad repeats. Seven to seventy
five micromolar substrate was incubated with 13 nM CDK9/cyclin T variants.
The final reaction conditions contained 150 mM NaCl, 10 mM MgCl2, 50 mM
HEPES pH 7.5, 2 mM DTT, and g-32P-labeled ATP as indicated. The reaction
mixture was incubated for 5 min at 30C and terminated by the addition of
sodium dodecyl sulfate (SDS) sample buffer. Samples were analyzed by
SDS-PAGE and subjected to autoradiography. At least three independent
measurements were done for each point in any experiment. Results were
confirmed in independent experiments. Curves were fitted using the software
Graphpad Prism version 5.02 (http://www.graphpad.com) and nonlinear
regression as described in the Supplemental Experimental Procedures section
of the Supplemental Information.
Modeling of a CDK9/Cyclin T/Substrate Complex
The polypeptide backbone of the CDK9FL/cyclin T259/DRB and CDK2/cyclin
A/peptide (1QMZ) complexes were superimposed on the C-terminal kinase
domain (residues 111–315 and 88–286, respectively) and the substrate peptide
was copied into the CDK9/cyclin T259 structure. The sequence of the CDK2
substrate peptide was subsequently modified to reflect the sequence of the
heptad repeat with Ser2 occupying the phospho-acceptor position.
ACCESSION NUMBERS
The atomic coordinates and structure factors have been deposited in the
Protein Data Bank (http://www.pdb.org) with accession codes 4EC8
(CDK9FL-cyclin T-DRB) and 4EC9 (CDK9FL-cyclin T).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, Supplemental
Experimental Procedures, four figures, and one table and can be found with
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